Drug Profile
Larotrectinib - Bayer/Loxo Oncology
Alternative Names: ARRY-470; BAY 2757556; Larotrectinib sulfate - Bayer/Loxo Oncology; LOXO 101; VITRAKVILatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Array BioPharma
- Developer Bayer; Loxo Oncology; National Cancer Institute (USA)
- Class Amides; Antineoplastics; Fluorobenzenes; Pyrazoles; Pyrimidines; Pyrrolidines; Small molecules; Tumour-agnostic therapies
- Mechanism of Action TrkA receptor antagonists; TrkB receptor antagonists; TrkC receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Solid tumours
- Phase II Histiocytosis; Non-Hodgkin's lymphoma
- Phase I/II CNS cancer
- No development reported Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 20 Oct 2023 Updated pooled efficacy and adverse events data from a phase I trial, phase I/II SCOUT trial and the phase II NAVIGATE in Solid tumors presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
- 28 Jun 2023 Updated efficacy and adverse events data from the phase II trial in NAVIGATE presented at the 25th World Congress on Gastrointestinal Cancer (WCGC-2023)
- 02 Jun 2023 Updated pooled efficacy data from the phase II NAVIGATE, phase I/II SCOUT and a phase I trial in Solid tumour presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)